New drug combo for untreated colon cancer with liver spread
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of drugs (Retlirafusp Alfa, Bevacizumab, and chemotherapy) with or without a short course of radiation for people with colorectal cancer that has spread only to the liver and who have not had any prior treatment. The goal is to see if this approach is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have colorectal cancer that has spread to the liver and it's the first time you're being treated for it.
- You need to be in good enough health to be considered for surgery (no major health issues that would prevent it).
- You must be able to swallow pills easily.
- You need to have at least one tumor that can be measured on scans.
- You cannot have serious heart problems, active infections, or autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an experimental drug (INCA33890) to standard chemotherapy and bevacizumab helps people with a certain type of advanced colorectal cancer. It is for those whose cancer has spread and has not been treated yet with systemic therapy.
This trial tests a combination of two chemotherapy drugs (FTD and tipiracil), a targeted therapy (bevacizumab), and a radiation treatment (radioembolization) for people with colorectal cancer that has spread mainly to the liver and hasn't responded to other treatments. The goal is to see if this combination can shrink tumors and help control the cancer.
This study tests a new combination of short-course radiation followed by two targeted drugs (fruquintinib and sintilimab) compared to standard therapy (bevacizumab and capecitabine) for people with advanced colorectal cancer who cannot tolerate strong chemotherapy. It aims to see if this gentler approach works as well or better.
This Phase 3 trial tests a treatment approach for colorectal cancer that cannot be removed with surgery at first but has spread only to the liver. It is intended for people whose tumor is RAS/BRAF “wild-type” and who are well enough to do daily activities, to see if the treatment can control the cancer better.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy and a targeted therapy (bevacizumab) to shrink liver metastases from colorectal cancer that cannot be surgically removed right now. The goal is to make the tumors small enough for surgery.
This trial tests a combination of radiation therapy, an immunotherapy drug (QL1706), and two targeted drugs (TAS-102 and bevacizumab) for people with advanced colorectal cancer that has spread and is not removable by surgery. It aims to see if this combination can help shrink tumors or slow cancer growth.
Hear when a new CRC (Colorectal Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.